Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01275131 | Completed Phase 1 Results

• 1 other identifier: HALO-117-105
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine if recombinant human hyaluronidase PH20 (rHuPH20) will change the exposure and action of approved insulin analogs when given by continuous subcutaneous insulin infusion (CSII) in participants with Type 1 diabetes mellitus (T1DM). This study is divided into Stage 1, 2, and 3. Stage 3 was started chronologically before Stage 2 and, prior to performing Stage 2, the Sponsor made the decision to terminate Stage 2. Stage 2 was not initiated due to a strategic business decision and termination was not based on safety or efficacy concerns. No participants were enrolled in Stage 2.

Conditions

Type 1 Diabetes Mellitus

Keywords

Insulin analog; Type 1 diabetes mellitus; Pharmacokinetic; Glucodynamic; Phase 1

Outcome Measures

Primary Outcomes (2)

• Early Insulin Exposure (%AUC[0-60]), Stage 1

  Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0-360}\]) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 120, 150, 180, 240, 300, and 360 minutes postdose during the euglycemic clamp.

  10 minutes predose up to 60 minutes postdose

• Early Exposure to Insulin (%AUC[0-60]), Stage 3

  Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0-360}) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 120, 150, 180, 240, 300, and 360 minutes postdose during the euglycemic clamp.

  10 minutes predose up to 60 minutes postdose on Days 2/7, 3/8, and 5/10

Secondary Outcomes (12)

• Maximum Glucose Infusion Rate (GIRmax), Stage 1

  0 up to 360 minutes postdose on Day 2/6 and Day 4/8

• Maximum Glucose Infusion Rate (GIRmax), Stage 3

  0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10

• Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 1

  0 up to 360 minutes postdose on Day 2/6 and Day 4/8

• Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 3

  0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10

• Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 1

  0 up to 360 minutes postdose on day 2/6 and Day 4/8

Study Arms (4)

Stage 1: Insulin aspart first, then insulin aspart-rHuPH20

ACTIVE COMPARATOR

Participants first received 0.15 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4. After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8.

Drug: Insulin aspart; Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

Stage 1: Insulin aspart-rHuPH20 first, then insulin aspart

ACTIVE COMPARATOR

Participants first received 0.15 units per kilogram (U/kg) insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4. After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart alone as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8.

Drug: Insulin aspart; Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

Stage 3: Insulin aspart first, then insulin aspart + rHuPH20

ACTIVE COMPARATOR

Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a sham injection was administered 2.5 hr prior to the 6-hr euglycemic clamp. After a 5- to 14-day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the 6-hr euglycemic clamp.

Drug: Insulin aspart; Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

Stage 3: Insulin aspart + rHuPH20 first, then insulin aspart

ACTIVE COMPARATOR

Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6- hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the euglycemic clamp . After a 5- to 14- day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a sham injection was administered 2.5 hr prior to the 6-hour euglycemic clamp.

Drug: Insulin aspart; Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

Interventions

Insulin aspart DRUG

Also known as: Novolog

Stage 1: Insulin aspart first, then insulin aspart-rHuPH20; Stage 1: Insulin aspart-rHuPH20 first, then insulin aspart; Stage 3: Insulin aspart + rHuPH20 first, then insulin aspart; Stage 3: Insulin aspart first, then insulin aspart + rHuPH20

Recombinant human hyaluronidase PH20 (rHuPH20) DRUG

Also known as: PH20, Hylenex

Stage 1: Insulin aspart first, then insulin aspart-rHuPH20; Stage 1: Insulin aspart-rHuPH20 first, then insulin aspart; Stage 3: Insulin aspart + rHuPH20 first, then insulin aspart; Stage 3: Insulin aspart first, then insulin aspart + rHuPH20

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female aged 18 to 65 years, inclusive. Females of child-bearing potential must use a standard and effective means of birth control for the duration of the study.
• Non-smoking participants with Type 1 diabetes mellitus (T1DM) treated with insulin for greater than or equal to 12 months. Non-smoking means abstinence from cigarettes and cigars for 3 months and negative cotinine screening tests.
• Body mass index (BMI) 18.0 to 35.0 kilograms per meter squared (kg/m\^2), inclusive.
• Glycosylated hemoglobin A1c (HbA1c) ≤10 % based on local laboratory results.
• Fasting C-peptide \<0.6 nanograms per milliliter (ng/mL).
• Current treatment with insulin \<90 units per day (U/d).
• Routine use of continuous subcutaneous insulin infusion (CSII) as the primary route of insulin administration.
• Participant should be in good general health based on medical history and physical examination, without medical conditions that might prevent the completion of study drug infusions and assessments required in this protocol.

You may not qualify if:

• Known or suspected allergy to any component of any of the study drugs in this trial.
• Previous enrollment in this trial (Exception: participants in Stage 1 are permitted to participate in Stage 2).
• Use of drugs that may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia. Participants taking maintenance doses of blood thinners (eg, Coumadin or heparin) will be excluded.
• Use of any long-acting insulin injection within 72 hours of Stage 1 or Stage 3.
• Recurrent major hypoglycemia or hypoglycemic unawareness, as judged by the Investigator.
• Current addiction to alcohol or substances of abuse as determined by the Investigator.
• Blood donation or phlebotomy (\>500 milliliters \[mL\]) within the previous 8 weeks of Screening. This applies both to new participants and to participants who have participated in Stage 1 and who wish to continue in Stage 2.
• Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate contraceptive measures (adequate contraceptive measures consist of sterilization, intra-uterine device \[IUD\], oral or injectable contraceptives, or barrier methods).
• Symptomatic gastroparesis.
• Receipt of any investigational drug within 4 weeks of Stage 1 or Stage 2.

Sponsors & Collaborators

• Halozyme Therapeutics: lead

Study Sites (1)

Profil Institute for Clinical Research

Chula Vista, California, 91911, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Interventions

Insulin Aspart

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Insulin, Short-Acting; Insulins; Pancreatic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Results Point of Contact

• Title: Vice President, Endocrinology Clinical Development
• Organization: Halozyme Therapeutics, Inc

(858)794-8889

Study Officials

• Linda Morrow, MD

  Profil Institute for Clinical Research, Inc.

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 10, 2011
• First Posted: January 12, 2011
• Study Start: January 1, 2011
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: July 25, 2014
• Results First Posted: July 25, 2014

Record last verified: 2014-06

Locations

US (1)